WillItSurvive
Medical technology and health companies · United States

CareDx

caredx.com ↗

CareDx runs lab tests that monitor organ transplant patients for rejection.

Defensible for now
Assessed 22 July 2026 · Evidence as of 22 July 2026
Real protection, with named pressure against it.
On the recordSince 22 July 2026 · Checkable from mid-2026 · Every call on the record Checkpoint: Supreme Court decides whether to hear Natera's false-advertising case against CareDx
The call

CareDx is growing fast and just turned profitable, but it shares its niche with Natera, and a Supreme Court ruling or a Medicare coverage cut could reshape the competition within the year.

CareDx runs a medical laboratory that tests transplant patients for organ rejection using proprietary tests called AlloSure and AlloMap. The business is hard to replace because hospitals have built these tests into their workflows, Medicare locks in the reimbursement rates, and CareDx owns years of patient data that rivals cannot easily recreate. However, Natera makes a competing test called Prospera that has been winning market share at some transplant centers since 2020, and a pending Supreme Court case could reshape the competitive landscape in the next six months. Revenue is growing 39 percent year-over-year and the company recently turned profitable, but the ultimate winner between CareDx and Natera remains genuinely uncertain.

Why
01
AI pressure: None apparent. AI models can't run wet-lab blood tests or replace Medicare-covered diagnostic assays; this is a lab services business, not a software one. Could AI do the core job? Unlikely.
02
Bigger players: Natera (Prospera test). Natera's Prospera test competes head to head in kidney and heart transplant monitoring and has reportedly won share from AlloSure since 2020. Could a giant copy it? Probably.
03
What protects it. Medicare coverage decisions, transplant center workflow habits, and years of longitudinal patient data make switching labs slow and risky for doctors.
What would change this call
Supreme Court decides whether to hear Natera's cert petition (filed Feb 9, 2026). Would resolve legal exposure over false-advertising dispute between the two rivals.
Center-level AlloSure vs. Prospera share data over next two quarters. Would show whether Natera is actually converting transplant centers away from CareDx.
Medicare LCD update on AlloSure coverage beyond the already-booked $7.5M H2 2026 headwind. Would show whether reimbursement risk is stabilizing or worsening.
Key numbers
  • Q1 2026 revenue $118M, up 39% YoY (2026-04-28)
  • FY2026 revenue guidance $447-465M (2026-04-28)
  • AlloSure Kidney has passed 300,000 cumulative tests (2025-07-26)
Named risks
  • Supreme Court cert decision in Natera litigation could go against CareDx, reviving damages exposure. Severity: high
  • Medicare LCD reimbursement cuts already costing an estimated $7.5 million in H2 2026 could worsen. Severity: medium
  • Integration risk from Naveris acquisition and Lab Products divestiture both landing in mid-2026. Severity: medium
  • Natera reported gaining AlloSure/Prospera share in some transplant centers since 2020. Severity: medium
  • Stock has shown extreme historical volatility, 52-week range $11.26 to near $40. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
Natera, Inc.contestingOngoing Lanham Act/patent litigation; CareDx filed SCOTUS cert petition Feb 9, 2026; Natera gaining share since 2020
Eurofins ScientificcontestingDescribed as a dominant player in parts of transplant diagnostics market per 2025-07-26 analysis
VeracytecontestingNoted as peer with Decipher tests having possible transplant-surveillance applicability (2025-07-26)
Thermo Fisher Scientific/One LambdacontestingIncumbent in HLA typing/reagents adjacent to CareDx's former Lab Products segment
Questions people ask
Is CareDx profitable in 2026?
Yes, CareDx turned GAAP net income positive in Q1 2026 at $2.8 million, versus a $10.4 million loss in Q1 2025, reported April 28, 2026. Revenue that quarter was $118 million, up 39% year over year, with FY2026 guidance raised to $447 to $465 million.
Who is CareDx's biggest competitor?
Natera, Inc. (NTRA) is CareDx's closest rival via its Prospera kidney, heart, and lung transplant-rejection test. Natera reported over $1.5 billion in 2024 revenue and has been described as gaining share against AlloSure in some transplant centers since 2020, alongside years of Lanham Act and patent litigation between the two firms.
Could AI replace CareDx's testing business?
No. CareDx's core revenue comes from regulated wet-lab molecular testing (AlloSure, AlloMap) tied to Medicare coverage and specimen processing that generic AI cannot replicate. Its own AI product, VANTx, launched March 5, 2026 on Databricks using Llama 3, is a data-analytics upsell layer, not a replacement for the lab business.
Is CareDx facing legal or reimbursement risk in 2026?
Yes. A 2021 qui tam suit was dismissed May 11, 2026, but CareDx filed a Supreme Court cert petition against Natera on February 9, 2026 over prior litigation, and FY2026 guidance already embeds an estimated $7.5 million six-month revenue hit from a Medicare Local Coverage Determination.
Is CareDx growing its revenue?
Yes. FY2025 total revenue was $380 million, up 14% year over year (reported February 24, 2026), and Q1 2026 revenue jumped 39% year over year to $118 million, driven by Testing Services growth of 48%, prompting CareDx to raise FY2026 guidance to $447 to $465 million on April 28, 2026.
Who owns CareDx and is it a safe employer?
CareDx is an independent public company (Nasdaq: CDNA) with no identified controlling shareholder, valued at roughly $1.99 billion market cap as of July 22, 2026. It reported 765 employees as of December 31, 2025, up 17.7% year over year, alongside newly profitable quarterly results.
Timeline
  • 2026-06-30Completed $171.2 million sale of Lab Products business to Eurobio Scientific
  • 2026-06-05CEO John Hanna cites about 750 employees at Jefferies healthcare conference
  • 2026-05-112021 qui tam suit against CareDx formally dismissed
  • 2026-04-28Q1 2026 revenue hits $118 million (+39% YoY), Naveris acquisition announced ($160M+$100M milestones)
  • 2026-03-05CareDx launches VANTx AI-powered clinical data analytics platform on Databricks/Llama 3
  • 2026-02-24FY2025 results: $380 million revenue (+14% YoY), $7.5M Medicare LCD impact flagged for FY2026
  • 2026-02-09CareDx files Supreme Court certiorari petition in Natera litigation
  • 2026-01-01CareDx and 10x Genomics announce ImmuneScape multiomics collaboration
Revision history
22 July 2026
First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.
In the same band
AbridgeSeegeneOlympus Corporation
More in Medical technology and health companies →
Sources